Showing 2341-2350 of 5909 results for "".
- Reichert to Distribute Imaging and Dry Eye Treatment Devices in the United Stateshttps://modernod.com/news/reichert-to-distribute-imaging-and-dry-eye-treatment-devices-in-the-united-states/2482016/Reichert Technologies, a business of AMETEK Inc., announced an exclusive partnership with SBM Sistemi of Italy to distribute SBM’s imaging and dry eye assessment and treatment devices in the United States. Financial terms of the deal were not disclosed. </
- NEI Study Shows How Genes in Retina Get Regulated During Developmenthttps://modernod.com/news/nei-study-shows-how-genes-in-retina-get-regulated-during-development/2482012/Using models of a retina grown in the lab, researchers at the National Eye Institute say they have mapped the 3D organization of genetic material of key developmental stages of human retinal formation. The findings lay a foundation for understanding clinical traits in many eye diseases, and
- Prevent Blindness President & CEO Jeff Todd to Lead 2024 National Health Council Board of Directorshttps://modernod.com/news/prevent-blindness-president-ceo-jeff-todd-to-lead-2024-national-health-council-board-of-directors/2482007/At the National Health Council (NHC) annual membership meeting, Jeff Todd, President & Chief Executive Officer of Prevent Blindness, was named the Chair of the NHC Board of Directors for 2024. “Jeff Todd is an excellent choice to lead our Board in 2024,” said R
- Tarsus Announces Topline Phase 2a Trial Results Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Miteshttps://modernod.com/news/tarsus-announces-topline-phase-2a-trial-results-evaluating-tp-03-for-the-treatment-of-mgd-in-patients-with-demodex-mites/2482004/Tarsus Pharmaceuticals announced topline results from the Ersa phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of meibomian gland disease (MGD) in patients with Demodex&nb
- New Report Calls for a National Eye Care Plan for England to Address Surging Patient Demandhttps://modernod.com/news/new-report-calls-for-a-national-eye-care-plan-for-england-to-address-surging-patient-demand/2482003/As part of Westminster Eye Health Day, stakeholders and experts from across the eye health sector have launched a new report laying out action required to improve eye care for patients in England. The initiative is led by "The Eyes Have It," a partnership of Macular Society, Fight
- National Eye Institute Selects Richard Lee, MD, PhD, as Clinical Directorhttps://modernod.com/news/national-eye-institute-selects-richard-lee-md-phd-as-clinical-director/2481999/The National Eye Institute (NEI) has chosen Richard Lee, MD, PhD, as the institute’s clinical director, overseeing clinical research and serving as clinical policy advisor for NEI. Dr. Lee comes to NEI from Moorfields Eye Hospital, where he’s had several roles since 2011, th
- Ciliatech Releases New Design of Glaucoma Surgical Device CIDhttps://modernod.com/news/ciliatech-releases-new-design-of-glaucoma-surgical-device-cid/2481993/Ciliatech announced the release of a new design of its CID (cilioscleral interpositioning device) following the filing of additional patents strengthening its IP (intellectual property). CID is the unique glaucoma surgical device used in the cilioscleral technique to lower IOP whil
- Signs of Glaucoma May Be Detectable Years in Advance of Disease Onsethttps://modernod.com/news/nih-signs-of-glaucoma-may-be-detectable-years-in-advance-of-disease-onset/2481989/Research funded by the National Eye Institute suggests that low density of pigment in the macula, the region of the retina required for sharp central vision, is associated with thinning of the retina and may serve as an early warning sign of glaucoma. The findings are based on nearly 400 women wh
- Genentech and Nvidia Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Developmenthttps://modernod.com/news/genentech-and-nvidia-enter-into-strategic-ai-research-collaboration-to-accelerate-drug-discovery-and-development/2481979/In a move aimed at speeding up drug discovery and development, Genentech announced a multi-year strategic research collaboration with Nvidia. Financial terms of the deal were not disclosed. The partnership will combine Genentech’s artificial intelligence
- Mass Eye and Ear Researchers Develop Potential Glaucoma Treatment Strategy to Guide Stem Cells to the Retinahttps://modernod.com/news/mass-eye-and-ear-researchers-develop-potential-glaucoma-treatment-strategy-to-guide-stem-cells-to-the-retina/2481977/A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy. In a new study, researchers changed the microenvironment in the eye in a way that enabled them to take st